

## References

1. Zuo H, Cattani-Cavaliere I, Musheshe N, Nikolaev VO, Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. *Pharmacol Ther.* 2019;197:225–42.
2. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J Pharmacol Exp Ther.* 2013;346:414–23.
3. Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. *Pulm Pharmacol Ther.* 2015;32:15–23.
4. Venkatasamy R, Spina D. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. *Br J Pharmacol.* 2016;173:2335–51.
5. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. *J Pharmacol Exp Ther.* 2006;318:840–8.
6. Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IMC, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. *Lancet Respir Med.* 2013;1:714–27.
7. Turner MJ, Luo Y, Thomas DY, Hanrahan JW. The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants. *Am J Physiol Lung Cell Mol Physiol.* 2020;318:L908–20.
8. Turner MJ, Matthes E, Billet A, Ferguson AJ, Thomas DY, Randell SH, et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. *Am J Physiol Lung Cell Mol Physiol.* 2016;310:L59–70.
9. Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: Randomized, double-blind, placebo-controlled, multicenter Phase III trials (the ENHANCE Trials). *Am J Respir Crit Care Med.* 2023;208:406–16.
10. Institute for Clinical and Economic Review. Ensifentrine for the treatment of chronic obstructive pulmonary disease: Effectiveness and value. 2024.
11. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025. Available from: <https://goldcopd.org/2025-gold-report/>. Accessed: 2024 Dec 11.
12. Valipour A, Fernandez-Bussy S, Ing AJ, Steinfors DP, Snell GI, Williamson JP, et al. Bronchial rheoplasty for treatment of chronic bronchitis. Twelve-month results from a multicenter clinical trial. *Am J Respir Crit Care Med.* 2020;202:681–9.
13. Sciruba FC, Dransfield MT, Kim V, Marchetti N, Comellas A, Hogarth DK, et al. Bronchial rheoplasty for chronic bronchitis: 2-year results from a US feasibility study with RheOx. *BMJ Open Respir Res.* 2023;10:e001710.
14. Dorscheid D, Shaipanich T, Liberman M, Martel S, Fortin M. Bronchial rheoplasty for chronic bronchitis: Results from a Canadian feasibility study with RheOx. *Chest.* 2021;160:A1860.
15. Canning BJ. Reflex regulation of airway smooth muscle tone. *J Appl Physiol.* 2006;101:971–85.
16. Valipour A, Shah PL, Pison C, Ninane V, Janssens W, Perez T, et al. Safety and dose study of targeted lung denervation in moderate/severe COPD patients. *Respiration.* 2019;98:329–39.
17. Slebos DJ, Shah PL, Herth FJF, Pison C, Schumann C, Hübner RH, et al. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. *Am J Respir Crit Care Med.* 2019;200:1477–86.
18. Godbout K, Gibson PG. Defining asthma-chronic obstructive pulmonary disease overlap. *Immunol Allergy Clin North Am.* 2022;42:507–19.
19. Plaza V, Álvarez F, Calle M, Casanova C, Cosío BG, López-Viña A, et al. Consensus on the asthma-COPD overlap syndrome (ACOS) between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). *Arch Bronconeumol.* 2017;53:443–9.

## References

20. Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. *Respir Res.* 2019;20:229.
21. Chen YC, Chang YP, Huang KT, Hsu PY, Hsiao CC, Lin MC. Unraveling the pathogenesis of asthma and chronic obstructive pulmonary disease overlap: Focusing on epigenetic mechanisms. *Cells.* 2022;11:1728.
22. Mekov E, Nuñez A, Sin DD, Ichinose M, Rhee CK, Maselli DJ, et al. Update on asthma-COPD overlap (ACO): A narrative review. *Int J Chron Obstruct Pulmon Dis.* 2021;16:1783–99.
23. Dey S, Eapen MS, Chia C, Gaikwad AV, Wark PAB, Sohal SS. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities. *Am J Physiol Lung Cell Mol Physiol.* 2022;322:L64–83.
24. Ghebre MA, Bafadhel M, Desai D, Cohen SE, Newbold P, Rapley L, et al. Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease. *J Allergy Clin Immunol.* 2015;135:63-72.e10.
25. Ghosh N, Choudhury P, Kaushik SR, Arya R, Nanda R, Bhattacharyya P, et al. Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO). *Respir Res.* 2020;21:126.
26. Park SY, Kim S, Kim JH, Kim SH, Lee T, Yoon SY, et al. A randomized, noninferiority trial comparing ICS + LABA with ICS + LABA + LAMA in asthma-COPD overlap (ACO) treatment: The ACO Treatment with Optimal Medications (ATOMIC) study. *J Allergy Clin Immunol Pract.* 2021;9:1304-1311.e2.
27. Hanania NA, Chipps BE, Griffin NM, Yoo B, Iqbal A, Casale TB. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. *J Allergy Clin Immunol.* 2019;143:1629-1633.e2.
28. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med.* 2018;6:117–26.
29. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. *Lancet Respir Med.* 2015;3:435–42.
30. Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. *Lancet Respir Med.* 2016;4:390–8.
31. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2015;192:523–5.
32. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting  $\beta$ -2 agonist efficacy in COPD. *Thorax.* 2016;71:118–25.
33. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. *Lancet Respir Med.* 2019;7:745–56.
34. Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: A post-hoc analysis of data from ETHOS. *Int J Chron Obstruct Pulmon Dis.* 2022;17:3061–73.
35. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. *N Engl J Med.* 2017;377:1613–29.
36. Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the prevention of COPD exacerbations. *N Engl J Med.* 2019;381:1023–34.
37. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. *N Engl J Med.* 2023;389:205–14.
38. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with blood eosinophil evidence of Type 2 inflammation. *N Engl J Med.* 2024;390:2274–83.

## References

39. Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. *Lancet Respir Med*. 2021;9:1288–98.
40. Singh D, Guller P, Reid F, Doffman S, Seppälä U, Psallidas I, et al. S92 FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD. *Thorax*. 2024;79:A68.
41. Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. *Lancet Respir Med*. 2022;10:469–77.
42. Singh D, Bafadhel M, Brightling CE, Rabe KF, Han MK, Bhutani M, et al. Tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease (COPD): Efficacy and safety from the Phase 2a COURSE study. *Am J Respir Crit Care Med*. 2024;209:A2782.
43. Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. *Chron Respir Dis*. 2017;14:377–84.
44. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots DR. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. *Chest*. 2012;142:432–9.
45. Cai Q, Triphuridat N, Zhu Y, You N, Yip R, Yankelevitz DF, et al. Bronchiectasis in low-dose CT screening for lung cancer. *Radiology*. 2022;304:437–47.
46. Chalmers JD, Polverino E, Crichton ML, Ringshausen FC, De Soyza A, Vendrell M, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). *Lancet Respir Med*. 2023;11:637–49.
47. O'Donnell AE. Bronchiectasis - A clinical review. *N Engl J Med*. 2022;387:533–45.
48. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. *Lancet (London, England)*. 2018;392:880–90.
49. Aksamit TR, O'Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Adult patients with bronchiectasis: A first look at the US Bronchiectasis Research Registry. *Chest*. 2017;151:982–92.
50. Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. *Cochrane database Syst Rev*. 2015;2015:CD008351.
51. Chalmers JD, Boersma W, Lonergan M, Jayaram L, Crichton ML, Karalus N, et al. Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. *Lancet Respir Med*. 2019;7:845–54.
52. Cordeiro R, Choi H, Haworth CS, Chalmers JD. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: Updated systematic review and meta-analysis. *Chest*. 2024;166:61–80.
53. Brode SK, Campitelli MA, Kwong JC, Lu H, Marchand-Austin A, Gershon AS, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. *Eur Respir J*. 2017;50:1700037.
54. Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, et al. Phase 2 trial of the DPP-1 Inhibitor brensocatib in bronchiectasis. *N Engl J Med*. 2020;383:2127–37.
55. Shoemark A, Shteinberg M, De Soyza A, Haworth CS, Richardson H, Gao Y, et al. Characterization of eosinophilic bronchiectasis: A European multicohort study. *Am J Respir Crit Care Med*. 2022;205:894–902.
56. Bendien SA, Kroes JA, van Hal LHG, Braunstahl GJ, Broeders MEAC, Oud KTM, et al. Real-world effectiveness of IL-5/5Ra targeted biologics in severe eosinophilic asthma with comorbid bronchiectasis. *J Allergy Clin Immunol Pract*. 2023;11:2724-2731.e2.
57. Dominic C, Pye H V., Mishra EK, Adriaenssens EM. Bacteriophages for bronchiectasis: treatment of the future? *Curr Opin Pulm Med*. 2024;30:235–42.
58. Stanojevic S, Kaminsky DA, Miller M, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J*. 2022;60:2101499.
59. Stolz D, Mkorombindo T, Schumann DM, Agusti A, Ash SY, Bafadhel M, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. *Lancet (London, England)*. 2022;400:921–72.

## References

60. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40:1324–43.
61. Allinson JP, Afzal S, Çolak Y, Jarvis D, Backman H, van den Berge M, et al. Changes in lung function in European adults born between 1884 and 1996 and implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies. *Lancet Respir Med*. 2022;10:83–94.
62. Bhakta NR, Bime C, Kaminsky DA, McCormack MC, Thakur N, Stanojevic S, et al. Race and ethnicity in pulmonary function test interpretation: An Official American Thoracic Society Statement. *Am J Respir Crit Care Med*. 2023;207:978–95.
63. Bhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, Jacobs DR, et al. Discriminative accuracy of FEV1:FVC thresholds for COPD-related hospitalization and mortality. *JAMA*. 2019;321:2438–47.
64. McCormack MC, Balasubramanian A, Matsui EC, Peng RD, Wise RA, Keet CA. Race, lung function, and long-term mortality in the National Health and Nutrition Examination Survey III. *Am J Respir Crit Care Med*. 2022;205:723–6.
65. Baugh AD, Shiboski S, Hansel NN, Ortega V, Barjakteravic I, Barr RG, et al. Reconsidering the utility of race-specific lung function prediction equations. *Am J Respir Crit Care Med*. 2022;205:819–29.
66. Brems JH, Balasubramanian A, Raju S, Putcha N, Fawzy A, Hansel NN, et al. Changes in spirometry interpretative strategies: Implications for classifying COPD and predicting exacerbations. *Chest*. 2024;166:294–303.
67. Spece LJ, Hee Wai T, Donovan LM, Duan KI, Plumley R, Crothers KA, et al. The impact of changing race-specific equations for lung function tests among veterans with chronic obstructive pulmonary disease. *Ann Am Thorac Soc*. 2024;21:1272–80.
68. Brems JH, Balasubramanian A, Psoter KJ, Shah P, Bush EL, Merlo CA, et al. Race-specific interpretation of spirometry: Impact on the lung allocation score. *Ann Am Thorac Soc*. 2023;20:1408–15.
69. Diao JA, He Y, Khazanchi R, Nguemeni Tiako MJ, Witonsky JI, Pierson E, et al. Implications of race adjustment in lung-function equations. *N Engl J Med*. 2024;390:2083–97.
70. Prentice HA, Mannino DM, Caldwell GG, Bush HM. Significant bronchodilator responsiveness and “reversibility” in a population sample. *COPD*. 2010;7:323–30.
71. Hutchinson J. On the capacity of the lungs, and on the respiratory functions, with a view of establishing a precise and easy method of detecting disease by the spirometer. *Med Chir Trans*. 1846;29:137–252.
72. Hawkes CP, Mostoufi-Moab S, McCormack SE, Grimberg A, Zemel BS. Sitting height to standing height ratio reference charts for children in the United States. *J Pediatr*. 2020;226:221-227.e15.
73. Barnes PJ. Emerging pharmacotherapies for COPD. *Chest*. 2008;134:1278–86.
74. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. *Nat Rev Immunol*. 2013;13:9–22.
75. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet*. 2000;356:1480–5.
76. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. *Thorax*. 2002;57:875–9.
77. Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? *Lancet Respir Med*. 2017;5:747–59.
78. Kolsum U, Damera G, Pham T-H, Southworth T, Mason S, Karur P, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. *J Allergy Clin Immunol*. 2017;140:1181-1184.e7.
79. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in COPD: the Copenhagen General Population Study. *Am J Respir Crit Care Med*. 2016;193:965–74.

## References

80. Mycroft K, Proboszcz M, Papińska-Goryca M, Krenke R, Górka K. Transcriptional profiles of peripheral eosinophils in chronic obstructive pulmonary disease and asthma-An exploratory study. *J Cell Mol Med.* 2024;28:e70110.
81. Linch SN, Kelly AM, Danielson ET, Pero R, Lee JJ, Gold JA. Mouse eosinophils possess potent antibacterial properties in vivo. *Infect Immun.* 2009;77:4976–82.
82. Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, et al. Lung microbiome dynamics in COPD exacerbations. *Eur Respir J.* 2016;47:1082–92.
83. Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. *Lancet Respir Med.* 2020;8:158–70.
84. Polverino F, Sin DD. Type 2 airway inflammation in COPD. *Eur Respir J.* 2024;63:2400150.
85. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med.* 2021;384:1800–9.
86. Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. *J Allergy Clin Immunol.* 2021;148:790–8.
87. Faiz A, Mahbub RM, Boedijono FS, Tomassen MI, Kooistra W, Timens W, et al. IL-33 expression is lower in current smokers at both transcriptomic and protein levels. *Am J Respir Crit Care Med.* 2023;208:1075–87.
88. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. *Nat Rev Immunol.* 2016;16:676–89.
89. Nissen G, Hinsenbrock S, Rausch TK, Stichtenoth G, Ricklefs I, Weckmann M, et al. Lung function of preterm children parsed by a polygenic risk score for adult COPD. *NEJM Evid.* 2023;2:EVIDo2200279.
90. Burke H, Wilkinson TMA. Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care. *Eur Respir Rev.* 2021;30:210041.
91. Martinez FJ, Agusti A, Celli BR, Han MLK, Allinson JP, Bhatt SP, et al. Treatment trials in young patients with chronic obstructive pulmonary disease and pre-chronic obstructive pulmonary disease patients: Time to move forward. *Am J Respir Crit Care Med.* 2022;205:275–87.
92. Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. *Chest.* 2012;141:73–80.
93. Pollack M, Nordon C, Rhodes K, Lobier M, Marshall J, Mullerova H, et al. Association between severe cardiovascular events and time following exacerbations of COPD: Meta-analyses of EXACOS-CV observational studies from 8 countries. *Am J r.* 2024;209:A1865.
94. Ezponda A, Casanova C, Divo M, Marín-Oto M, Cabrera C, Marín JM, et al. Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort. *Respirology.* 2022;27:286–93.
95. Konstantinoudis G, Minelli C, Vicedo-Cabrera AM, Ballester J, Gasparrini A, Blangiardo M. Ambient heat exposure and COPD hospitalisations in England: a nationwide case-crossover study during 2007-2018. *Thorax.* 2022;77:1098–104.
96. Morgan AD, Rothnie KJ, Bhaskaran K, Smeeth L, Quint JK. Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. *Thorax.* 2018;73:877–9.
97. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? *Ther Adv Respir Dis.* 2018;12:1753465817750524.
98. Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, et al. Reframing the association and significance of co-morbidities in heart failure. *Eur J Heart Fail.* 2016;18:744–58.
99. Jasinska-Piadlo A, Campbell P. Management of patients with heart failure and preserved ejection fraction. *Heart.* 2023;109:874–83.
100. Axson EL, Sundaram V, Bloom CI, Bottle A, Cowie MR, Quint JK. Temporal trends in the incidence of heart failure among patients with chronic obstructive pulmonary disease and its association with mortality. *Ann Am Thorac Soc.* 2020;17:939–48.

## References

101. Anker SD, Usman MS, Anker MS, Butler J, Böhm M, Abraham WT, et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. *Eur J Heart Fail.* 2023;25:936–55.
102. Freixa X, Portillo K, Paré C, Garcia-Aymerich J, Gomez FP, Benet M, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. *Eur Respir J.* 2013;41:784–91.
103. Mooney L, Hawkins NM, Jhund PS, Redfield MM, Vaduganathan M, Desai AS, et al. Impact of chronic obstructive pulmonary disease in patients with heart failure with preserved ejection fraction: Insights from PARAGON-HF. *J Am Heart Assoc.* 2021;10:e021494.
104. Gulea C, Zakeri R, Quint JK. Differences in outcomes between heart failure phenotypes in patients with coexistent chronic obstructive pulmonary disease: A cohort study. *Ann Am Thorac Soc.* 2022;19:971–80.
105. Xu S, Gu Z, Zhu W, Feng S. Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction. *ESC Heart Fail.* 2024;Online early.
106. Axson EL, Bottle A, Cowie MR, Quint JK. Relationship between heart failure and the risk of acute exacerbation of COPD. *Thorax.* 2021;76:807–14.
107. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation.* 2018;138:861–70.
108. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J.* 2022;43:3618–731.
109. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. *Chest.* 2005;127:1531–6.
110. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. *Thorax.* 1981;36:752–8.
111. Kessler R, Faller M, Fourgaut G, Menecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1999;159:158–64.
112. Vizza CD, Hoeper MM, Huscher D, Pittrow D, Benjamin N, Olsson KM, et al. Pulmonary hypertension in patients with COPD: Results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). *Chest.* 2021;160:678–89.
113. Kovacs G, Avian A, Bachmaier G, Troester N, Tornyo A, Douschan P, et al. Severe pulmonary hypertension in COPD: Impact on survival and diagnostic approach. *Chest.* 2022;162:202–12.
114. Kovacs G, Bartolome S, Denton CP, Gatzoulis MA, Gu S, Khanna D, et al. Definition, classification and diagnosis of pulmonary hypertension. *Eur Respir J.* 2024;64:2401324.
115. Kovacs G, Agusti A, Barberá JA, Celli B, Criner G, Humbert M, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease - is there a pulmonary vascular phenotype? *Am J Respir Crit Care Med.* 2018;198:1000–11.
116. Arif R, Pandey A, Zhao Y, Arsenault-Mehta K, Khoujah D, Mehta S. Treatment of pulmonary hypertension associated with COPD: a systematic review. *ERJ Open Research.* 2022;8:00348–2021.
117. Khateeb J, Fuchs E, Khamaisi M. Diabetes and lung disease: A neglected relationship. *Rev Diabet Stud.* 2019;15:1–15.
118. Pradhan R, Lu S, Yin H, Yu OHY, Ernst P, Suissa S, et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. *BMJ.* 2022;379:e071380.
119. Li Y, Gao H, Zhao L, Wang J. Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation. *Clin Respir J.* 2022;16:487–96.
120. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2024;74:229–63.

## References

121. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. *CA Cancer J Clin*. 2024;74:12–49.
122. Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. *Am J Respir Crit Care Med*. 2007;176:285–90.
123. Houghton AMG. Mechanistic links between COPD and lung cancer. *Nat Rev Cancer*. 2013;13:233–45.
124. American Cancer Society. Lung cancer causes, risk factors, and prevention. Available from: <https://www.cancer.org/cancer/types/lung-cancer/causes-risks-prevention.html>. Accessed: 2025 Jan 18.
125. Young RP, Hopkins RJ. Link between COPD and lung cancer. *Respir Med*. 2010;104:758–9.
126. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. *Chest*. 2010;138:1295–302.
127. Riondino S, Rosenfeld R, Formica V, Morelli C, Parisi G, Torino F, et al. Effectiveness of immunotherapy in non-small cell lung cancer patients with a diagnosis of COPD: Is this a hidden prognosticator for survival and a risk factor for immune-related adverse events? *Cancers (Basel)*. 2024;16:1251.
128. Schwartz AG, Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2006;173:16–22.
129. Young RP, Hopkins RJ, Gamble GD, Etzel C, El-Zein R, Crapo JD. Genetic evidence linking lung cancer and COPD: a new perspective. *Appl Clin Genet*. 2011;4:99–111.
130. Rivera MP, Tanner NT, Silvestri GA, Detterbeck FC, Tammemägi MC, Young RP, et al. Incorporating coexisting chronic illness into decisions about patient selection for lung cancer screening. An official American Thoracic Society research statement. *Am J Respir Crit Care Med*. 2018;198:e3–13.
131. Iaccarino JM, Silvestri GA, Wiener RS. Patient-level trajectories and outcomes after low-dose CT screening in the National Lung Screening Trial. *Chest*. 2019;156:965–71.
132. Young RP, Ward RC, Scott RJ, Gamble GD, Silvestri G. Airflow limitation and mortality during cancer screening in the National Lung Screening Trial: why quantifying airflow limitation matters. *Thorax*. 2023;78:690–7.
133. Passiglia F, Cinquini M, Bertolaccini L, Del Re M, Facchinetti F, Ferrara R, et al. Benefits and harms of lung cancer screening by chest computed tomography: A systematic review and meta-analysis. *J Clin Oncol*. 2021;39:2574–85.
134. World Health Organization. Global diffusion of eHealth: making universal health coverage achievable: report of the third global survey on eHealth. 2016.
135. Sculley JA, Musick H, Krishnan JA. Telehealth in chronic obstructive pulmonary disease: before, during, and after the coronavirus disease 2019 pandemic. *Curr Opin Pulm Med*. 2022;28:93–8.
136. Janjua S, Carter D, Threapleton CJD, Prigmore S, Disler RT. Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD). *Cochrane Database Syst Rev*. 2021;7:CD013196.
137. Cox NS, Dal Corso S, Hansen H, McDonald CF, Hill CJ, Zanaboni P, et al. Telerehabilitation for chronic respiratory disease. *Cochrane Database Syst Rev*. 2021;1:CD013040.
138. Bhatt SP, Casaburi R, Mosher CL, Rochester CL, Garvey C. Telehealth pulmonary rehabilitation: A call for minimum standards. *Am J Respir Crit Care Med*. 2024;210:145–6.
139. Kermelley SB, Bourbeau J. eHealth in self-managing at a distance patients with COPD. *Life*. 2022;12:773.
140. Bourbeau J, Julien M, Maltais F, Rouleau M, Beaudré A, Bégin R, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. *Arch Intern Med*. 2003;163:585–91.
141. Gadoury MA, Schwartzman K, Rouleau M, Maltais F, Julien M, Beaudré A, et al. Self-management reduces both short- and long-term hospitalisation in COPD. *Eur Respir J*. 2005;26:853–7.
142. Pearce G, Parke HL, Pinnock H, Epiphaniou E, Bourne CLA, Sheikh A, et al. The PRISMS taxonomy of self-management support: derivation of a novel taxonomy and initial testing of its utility. *J Health Serv Res Policy*. 2016;21:73–82.

## References

143. Hanlon P, Daines L, Campbell C, Mckinstry B, Weller D, Pinnock H. Telehealth interventions to support self-management of long-term conditions: A systematic metareview of diabetes, heart failure, asthma, chronic obstructive pulmonary disease, and cancer. *J Med Internet Res*. 2017;19:e172.
144. Shah AJ, Althobiani MA, Saigal A, Ogbonnaya CE, Hurst JR, Mandal S. Wearable technology interventions in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *NPJ Digit Med*. 2023;6:222.
145. Patel N, Kinmond K, Jones P, Birks P, Spiteri MA. Validation of COPDPredictTM: Unique combination of remote monitoring and exacerbation prediction to support preventative management of COPD exacerbations. *Int J Chron Obstruct Pulmon Dis*. 2021;16:1887–99.
146. Tilquin F, Le Liepvre S, Le Guillou Y, Balbolia S, Cornu J, Esteve V, et al. AECOPD prediction through a remote monitoring system. *Eur Respir J*. 2024;64:44046.
147. Wu R, de Lara E, Liaqat D, Liaqat S, Chen JL, Son T, et al. Feasibility of a wearable self-management application for patients with COPD at home: a pilot study. *BMC Med Inform Decis Mak*. 2024;24:66.
148. NowSecure. 2022 mhealth app security and privacy trends. Available from: <https://www.nowsecure.com/blog/2022/03/09/2022-mhealth-app-security-and-privacy-trends/>. Accessed: 2024 Nov 17.
149. Peretz D, Arnaert A, Ponzoni NN. Determining the cost of implementing and operating a remote patient monitoring programme for the elderly with chronic conditions: A systematic review of economic evaluations. *J Telemed Telecare*. 2018;24:13–21.
150. Uscher-Pines L, Mehrotra A. The effect of telehealth on spending-reframing the debate. *JAMA*. 2024;332:1513–4.
151. Wilkinson TMA, Aris E, Bourne SC, Clarke SC, Peeters M, Pascal TG, et al. Drivers of year-to-year variation in exacerbation frequency of COPD: analysis of the AERIS cohort. *ERJ Open Research*. 2019;5:00248–2018.
152. Seemungal TAR, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. *Eur Respir J*. 2000;16:677–83.